Background Long-acting injectable antipsychotics (LAIAs) are an efficacious and well-
tolerated treatment in adults with schizophrenia spectrum disorders (SSD). However, there is …

Objectives: While long-lasting antipsychotics (LLA) were specifically developed to address
the problem of adherence in patients with chronic psychiatric disorders, their role in pediatric …

Objectives: Long-acting injectable (LAI) antipsychotic medications are being prescribed to
children and adolescents along a broad age range from 2 to 17 years old. However, there is …

Background: Paliperidone is FDA-approved for schizophrenia aged 12–17. However, the
pharmacologic portfolio, extrapolation from adult studies, and the long track record of the …

Il delirium è una condizione clinica classificata, nel DSM-5, tra i disturbi neurocognitivi.
L'eziologia è molteplice e spesso a esito fatale. Il presente contributo si pone come obiettivo …

In the psychiatry department, the biperiden dose was increased to 6 mg/d, and diazepam
was increased to 10 mg/d. During follow-ups, complaints of fatigue, loss of appetite, and …

This chapter provides a comprehensive review of recently published case reports and case
series detailing adverse effects and/or drug interactions associated with various first-and …

Objectives: While AU3 c long-lasting injectable antipsychotics (LLA) were specifically
developed to address the problem of adherence in patients with chronic psychiatric …

Conclusion: Drug complications and drug side effects exacerbated the patient's
schizophrenia due to the patient's limited access to new generation drugs. Public health …

Paliperidone palmitate (PP) is a long-acting antipsychotic administered intramuscularly once
a month in the acute and maintenance treatments of schizophrenia. It has been reported to …